Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo

Article2023

The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.

Irene L. M. Reijers, Alexander M. Menzies, Judith M. Versluis, Robyn P.M. Saw, Winan J. van Houdt, Ellen Kapiteijn, Astrid Aplonia Maria Van Der Veldt, Karijn P.M. Suijkerbuijk, Hanna Eriksson, Geke A.P. Hospers, W. Martin C. Klop, Marta López‐Yurda, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Andrew J. Spillane, Richard A Scolyer, Bart A. van de Wiel, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long, Christian U. Blank

Article2022

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C.J. van Akkooi, Judith M. Versluis, N.M.J. Van Den Heuvel, Robyn P.M. Saw, Thomas E. Pennington, Ellen Kapiteijn, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk, Geke A.P. Hospers, Elisa A. Rozeman, W. Martin C. Klop, Winan J. van Houdt, Karolina Sikorska, Jos A. van der Hage, Dirk J. Grünhagen, Michel W.J.M. Wouters, Arjen J. Witkamp, Charlotte L. Zuur, Judith Lijnsvelt, A. Torres Acosta,

Article2021

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers, Robyn P.M. Saw, Judith M. Versluis, Oscar Krijgsman, Petros Dimitriadis, Karolina Sikorska, Bart A. van de Wiel, Hanna Eriksson, Maria Gonzalez, A. Torres Acosta, Lindsay G. Grijpink-Ongering, Kerwin F. Shannon, John B.A.G. Haanen, Jonathan R. Stretch, Sydney Ch’ng, Omgo E. Nieweg, Henk Mallo, S. Adriaansz, Ron Kerkhoven, Sten Cornelissen, Annegien Broeks, ,

Article2022

Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.

Judith M. Versluis, Karolina Sikorska, Elisa A. Rozeman, Alexander M. Menzies, Hanna Eriksson, W. Martin C. Klop, Robyn P.M. Saw, Bart A. van de Wiel, Richard A Scolyer, Johannes V. van Thienen, Henk Mallo, Maria Gonzalez, Alex Torres Acosta, Lindsay G. Grijpink-Ongering, Anja van der Wal, John B.A.G. Haanen, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long, Christian U. Blank

Article2019

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

Irene L. M. Reijers, Elisa A. Rozeman, Alexander M. Menzies, Bart A. van de Wiel, Hanna Eriksson, Karijn P.M. Suijkerbuijk, Astrid Aplonia Maria Van Der Veldt, Ellen Kapiteijn, Geke A.P. Hospers, W. Martin C. Klop, Andrew J. Spillane, Richard A Scolyer, Inge Marie Svane, Lars Bastholt, Henrik Schmidt, James Larkin, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long, Christian U. Blank

Discussion(0)

Related publications